- Home
- PYXS vs RLMD Comparison
PYXS vs RLMD Comparison
Compare PYXS & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYXS
- RLMD
- Stock Information
- Founded
- PYXS 2018
- RLMD 2004
- Country
- PYXS United States
- RLMD United States
- Employees
- PYXS N/A
- RLMD N/A
- Industry
- PYXS Biotechnology: Pharmaceutical Preparations
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- PYXS Health Care
- RLMD Health Care
- Exchange
- PYXS Nasdaq
- RLMD Nasdaq
- Market Cap
- PYXS 79.4M
- RLMD 67.7M
- IPO Year
- PYXS 2021
- RLMD N/A
- Fundamental
- Price
- PYXS $3.48
- RLMD $2.47
- Analyst Decision
- PYXS Strong Buy
- RLMD Hold
- Analyst Count
- PYXS 5
- RLMD 2
- Target Price
- PYXS $7.75
- RLMD $1.00
- AVG Volume (30 Days)
- PYXS 877.2K
- RLMD 317.2K
- Earning Date
- PYXS 11-11-2025
- RLMD 11-07-2025
- Dividend Yield
- PYXS N/A
- RLMD N/A
- EPS Growth
- PYXS N/A
- RLMD N/A
- EPS
- PYXS N/A
- RLMD N/A
- Revenue
- PYXS $2,820,000.00
- RLMD N/A
- Revenue This Year
- PYXS N/A
- RLMD N/A
- Revenue Next Year
- PYXS N/A
- RLMD N/A
- P/E Ratio
- PYXS N/A
- RLMD N/A
- Revenue Growth
- PYXS N/A
- RLMD N/A
- 52 Week Low
- PYXS $0.83
- RLMD $0.24
- 52 Week High
- PYXS $5.39
- RLMD $3.98
- Technical
- Relative Strength Index (RSI)
- PYXS 60.49
- RLMD 64.27
- Support Level
- PYXS $3.17
- RLMD $1.98
- Resistance Level
- PYXS $3.75
- RLMD $2.49
- Average True Range (ATR)
- PYXS 0.31
- RLMD 0.19
- MACD
- PYXS -0.05
- RLMD 0.00
- Stochastic Oscillator
- PYXS 33.62
- RLMD 97.09
About PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.